Pfizer Withdraws Sickle Cell Treatment Oxbryta from Global Markets Due to Safety Concerns, $5.4 Billion Acquisition Impacted

Sep 25, 2024, 09:30 PM

Pfizer Inc. announced it is voluntarily withdrawing all lots of its sickle cell disease treatment, Oxbryta (voxelotor), from worldwide markets due to safety concerns. The decision follows data indicating an imbalance in vaso-occlusive crises and fatal events associated with the drug. Oxbryta was acquired by Pfizer in a $5.4 billion deal with Global Blood Therapeutics in 2022.